Hodgkin's lymphoma	is a	cancer
Hodgkin's lymphoma	is a	lymphoid cancer
Hodgkin's lymphoma	arises in	lymph nodes
Hodgkin's lymphoma	presents with	lymphadenopathy
Hodgkin's lymphoma	presents with	B symptoms
Hodgkin's lymphoma	associated with	Epstein-Barr virus
Hodgkin's lymphoma	contains	Reed-Sternberg cells
Reed-Sternberg cells	are	malignant B-lymphocytes
Hodgkin's lymphoma	histology	nodular sclerosis
Hodgkin's lymphoma	histology	lymphocyte-rich
Hodgkin's lymphoma	histology	nodular lymphocyte-predominant
Hodgkin's lymphoma	staging	Ann Arbor
Hodgkin's lymphoma	treatment	ABVD regimen
Hodgkin's lymphoma	treatment	BEACOPP regimen
ABVD regimen	includes	doxorubicin
ABVD regimen	includes	bleomycin
ABVD regimen	includes	vinblastine
ABVD regimen	includes	dacarbazine
Doxorubicin	is a	anthracycline
Bleomycin	is a	cytotoxic agent
Vinblastine	is a	microtubule inhibitor
Dacarbazine	is a	alkylating agent
Hodgkin's lymphoma	treated with	radiotherapy
Hodgkin's lymphoma	treated with	chemotherapy
Radiotherapy	used for	localized disease
Chemotherapy	used for	systemic disease
Chemotherapy	causes	neutropenia
Chemotherapy	causes	alopecia
Chemotherapy	causes	nausea
Doxorubicin	causes	cardiotoxicity
Bleomycin	causes	pulmonary toxicity
Vinblastine	causes	neuropathy
Dacarbazine	causes	nausea
Autologous stem cell transplantation	used for	Hodgkin's lymphoma relapse
Hodgkin's lymphoma	prognosis	favorable prognosis
Hodgkin's lymphoma	incidence	bimodal distribution
EBV infection	associated with	Hodgkin's lymphoma
PET-CT	used for	staging
Staging	determines	treatment plan
Ann Arbor staging	classifies	disease extent
Hodgkin's lymphoma	age group	young adults
Hodgkin's lymphoma	age distribution	bimodal
Lymph node biopsy	yields	diagnostic tissue
Hodgkin's lymphoma	diagnosis	biopsy confirmation
Lymph node biopsy	confirms	Hodgkin's lymphoma
CD30 positivity	indicates	Hodgkin's lymphoma
CD15 positivity	indicates	Hodgkin's lymphoma
PET-CT	predicts	treatment response
Treatment response	correlates with	survival
Survival	depends on	stage at diagnosis
Staging	influences	therapy intensity
Therapy intensity	determines	radiation field
Radiation field	is defined by	stage
Radiotherapy	long-term toxicity	hypothyroidism
Radiotherapy	dose	fractionation
Fertility preservation	considered for	Hodgkin's lymphoma patients
Pediatric Hodgkin's lymphoma	incidence	rare
Growth factors	support	chemotherapy-induced neutropenia
Infection risk	increases	chemotherapy
Chemotherapy	reduces	tumor burden
Tumor burden	declines with	chemotherapy
Radiation therapy	reduces	local recurrence
Relapse	requires	salvage therapy
Salvage therapy	includes	high-dose chemotherapy
High-dose chemotherapy	followed by	stem cell rescue
Stem cell rescue	used for	Hodgkin's lymphoma relapse
NCCN guidelines	guide	Hodgkin's lymphoma management
Survivorship planning	addresses	secondary malignancy risk
Secondary malignancy risk	elevated by	radiotherapy
Radiotherapy	dose	fractionation strategy
Fractionation strategy	aims for	toxicity reduction
Prognostic factor	includes	stage
Stage	classification	early
Prognostic factor	includes	histology
Histology	influences	prognosis
Extranodal involvement	occurs with	advanced disease
Chemotherapy	interacts with	radiation therapy
Combination therapy	preferred for	early-stage disease
Observation strategy	used for	complete remission
Complete remission	achieved by	combination therapy
Clinical trial	evaluates	new regimens
New regimens	tested in	clinical trial
Radiation therapy	is adjuvant	therapy
Chemotherapy	is neoadjuvant	therapy
Quality of life	affected by	Hodgkin's lymphoma treatment
Anemia	associated with	Hodgkin's lymphoma
Infection	risk with	immunosuppression
Immunosuppression	results from	chemotherapy
Vaccination	recommended for	Hodgkin's lymphoma survivors
Hodgkin's lymphoma	comorbidity	cardiovascular disease
Doxorubicin	cardiotoxicity	dose-dependency
Secondary malignancy	risk	lifetime
Lipid profile	monitoring	Hodgkin's lymphoma therapy
Tumor microenvironment	influences	treatment response
Positron emission tomography	used for	metabolic imaging
Metabolic imaging	provides	staging information
Steroids	used for	symptom management
Steroid therapy	causes	mood changes
Molecular testing	informs	targeted therapy
Targeted therapy	used for	refractory Hodgkin's lymphoma
